ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Nexavar receives final appraisal for primary liver cancer
August 11, 2017NICE has released a Final Appraisal Document recommending Nexavar for the treatment of patients with advanced hepatocellular carcinoma… -
First new promising treatment in a decade for primary liver cancer patients
May 02, 2017Results of the SARAH trial demonstrate that SIRT resulted in median overall survival (OS) of 8.0 months compared to 9.9 months with sorafenib (p=0.179), in patients with locally advanced and inoperable hepatocellular carcinoma (HCC). -
Q BioMed in Cancer Development Pact
February 08, 2017Q BioMed has entered into an agreement with the Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB) to develop a chemotherapeutic technology to treat liver cancer. -
FDA grants priority review for Bayer’s liver cancer treatment
January 05, 2017The US Food and Drug Administration (FDA) has granted priority review status for the supplemental new drug application for Stivarga (regorafenib, Bayer), as a second line systemic treatment of patients with hepatocellular carcinoma (HCC) in the US.
Pharma Sources Insight January 2025
